Renaissance of leptin for obesity therapy

Research output: Contribution to journal › Review › Research › peer-review

Standard

Renaissance of leptin for obesity therapy. / Quarta, Carmelo; Sánchez-Garrido, Miguel A; Tschöp, Matthias H; Clemmensen, Christoffer.

In: Diabetologia, Vol. 59, No. 5, 05.2016, p. 920-7.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Quarta, C, Sánchez-Garrido, MA, Tschöp, MH & Clemmensen, C 2016, 'Renaissance of leptin for obesity therapy', Diabetologia, vol. 59, no. 5, pp. 920-7. https://doi.org/10.1007/s00125-016-3906-7

APA

Quarta, C., Sánchez-Garrido, M. A., Tschöp, M. H., & Clemmensen, C. (2016). Renaissance of leptin for obesity therapy. Diabetologia, 59(5), 920-7. https://doi.org/10.1007/s00125-016-3906-7

Vancouver

Quarta C, Sánchez-Garrido MA, Tschöp MH, Clemmensen C. Renaissance of leptin for obesity therapy. Diabetologia. 2016 May;59(5):920-7. https://doi.org/10.1007/s00125-016-3906-7

Author

Quarta, Carmelo ; Sánchez-Garrido, Miguel A ; Tschöp, Matthias H ; Clemmensen, Christoffer. / Renaissance of leptin for obesity therapy. In: Diabetologia. 2016 ; Vol. 59, No. 5. pp. 920-7.

Bibtex

@article{2814d0395ba3484b9f9fae8306a97363,
title = "Renaissance of leptin for obesity therapy",
abstract = "Diet-induced obesity and its metabolic comorbidities constitute an overwhelming health crisis and there is an urgent need for safe and effective pharmacological interventions. Being largely shelved for decades, scientists are now revisiting the anti-obesity virtues of leptin. Whereas it remains evident that leptin as a stand-alone therapy is not an effective approach, the potential for employing sensitising pharmacology to unleash the weight-lowering properties of leptin has injected new hope into the field. Fascinatingly, these leptin-sensitising agents seem to act via distinct metabolic pathways and may thus, in parallel with their clinical development, serve as important research tools to progress our understanding of the molecular, physiological and behavioural pathways underlying energy homeostasis and obesity pathophysiology. This review summarises a presentation given at the 'Is leptin coming back?' symposium at the 2015 annual meeting of the EASD. It is accompanied by two other reviews on topics from this symposium (by Thomas Meek and Gregory Morton, DOI: 10.1007/s00125-016-3898-3 , and by Gerald Shulman and colleagues, DOI: 10.1007/s00125-016-3909-4 ) and an overview by the Session Chair, Ulf Smith (DOI: 10.1007/s00125-016-3894-7 ).",
keywords = "Animals, Body Weight, Energy Metabolism, Homeostasis, Humans, Leptin, Obesity, Signal Transduction, Journal Article, Review",
author = "Carmelo Quarta and S{\'a}nchez-Garrido, {Miguel A} and Tsch{\"o}p, {Matthias H} and Christoffer Clemmensen",
year = "2016",
month = may,
doi = "10.1007/s00125-016-3906-7",
language = "English",
volume = "59",
pages = "920--7",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Renaissance of leptin for obesity therapy

AU - Quarta, Carmelo

AU - Sánchez-Garrido, Miguel A

AU - Tschöp, Matthias H

AU - Clemmensen, Christoffer

PY - 2016/5

Y1 - 2016/5

N2 - Diet-induced obesity and its metabolic comorbidities constitute an overwhelming health crisis and there is an urgent need for safe and effective pharmacological interventions. Being largely shelved for decades, scientists are now revisiting the anti-obesity virtues of leptin. Whereas it remains evident that leptin as a stand-alone therapy is not an effective approach, the potential for employing sensitising pharmacology to unleash the weight-lowering properties of leptin has injected new hope into the field. Fascinatingly, these leptin-sensitising agents seem to act via distinct metabolic pathways and may thus, in parallel with their clinical development, serve as important research tools to progress our understanding of the molecular, physiological and behavioural pathways underlying energy homeostasis and obesity pathophysiology. This review summarises a presentation given at the 'Is leptin coming back?' symposium at the 2015 annual meeting of the EASD. It is accompanied by two other reviews on topics from this symposium (by Thomas Meek and Gregory Morton, DOI: 10.1007/s00125-016-3898-3 , and by Gerald Shulman and colleagues, DOI: 10.1007/s00125-016-3909-4 ) and an overview by the Session Chair, Ulf Smith (DOI: 10.1007/s00125-016-3894-7 ).

AB - Diet-induced obesity and its metabolic comorbidities constitute an overwhelming health crisis and there is an urgent need for safe and effective pharmacological interventions. Being largely shelved for decades, scientists are now revisiting the anti-obesity virtues of leptin. Whereas it remains evident that leptin as a stand-alone therapy is not an effective approach, the potential for employing sensitising pharmacology to unleash the weight-lowering properties of leptin has injected new hope into the field. Fascinatingly, these leptin-sensitising agents seem to act via distinct metabolic pathways and may thus, in parallel with their clinical development, serve as important research tools to progress our understanding of the molecular, physiological and behavioural pathways underlying energy homeostasis and obesity pathophysiology. This review summarises a presentation given at the 'Is leptin coming back?' symposium at the 2015 annual meeting of the EASD. It is accompanied by two other reviews on topics from this symposium (by Thomas Meek and Gregory Morton, DOI: 10.1007/s00125-016-3898-3 , and by Gerald Shulman and colleagues, DOI: 10.1007/s00125-016-3909-4 ) and an overview by the Session Chair, Ulf Smith (DOI: 10.1007/s00125-016-3894-7 ).

KW - Animals

KW - Body Weight

KW - Energy Metabolism

KW - Homeostasis

KW - Humans

KW - Leptin

KW - Obesity

KW - Signal Transduction

KW - Journal Article

KW - Review

U2 - 10.1007/s00125-016-3906-7

DO - 10.1007/s00125-016-3906-7

M3 - Review

C2 - 26983921

VL - 59

SP - 920

EP - 927

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 5

ER -

ID: 186640162